

EM014773813US

Attorney Docket No.: VOS/048 RCE (003747-0088-101)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mohammed Shahid
Application No. : 10/783,821 Confirmation No.: 7055
Group Art Unit : 1623
Examiner Elli Peselev
Filed : February 20, 2004
For : SYNTHESIS OF SOLANUM GLYCOSIDES

New York, New York
October 14, 2008

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicant hereby makes the following document of record in the above-identified patent application:

OTHER DOCUMENT

Chang LC, et al. The Rhamnose Moiety of Solamargine Plays a Crucial Role in Triggering Cell Death by Apoptosis, *Biochemical and Biophysical Research Communications*, Volume 242, Issue 1, 6 January 1998, Pages 21-25

A copy of the aforementioned document, which is listed on the accompanying Form SB/08B, is enclosed herewith.

Application No. 10/783,821

Information Disclosure Statement dated October 14, 2008

It is respectfully requested that this document be (1) fully considered by the Patent and Trademark Office during examination of this application; and (2) printed on any patent which may issue on this application. Applicant requests that a copy of Form SB/08B, as considered and initialed by the Examiner, be returned with the next communication.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


Please charge our Deposit Account No. 06-1075 Order No. 003747-0088-101 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or

Application No. 10/783,821

Information Disclosure Statement dated October 14, 2008

which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-1075, under Order No. 003747-0088-101.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicant

ROPES & GRAY LLP

Customer No. 1473

1211 Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000

Fax: (212) 596-9090